CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its portfolio of ...

Blocking a protein known as CDK7 could prevent heart damage associated with a commonly used cancer chemotherapy medication, according to a study led by scientists at Washington State University.

CDK4/6 inhibitors like Pfizer’s Ibrance have changed the treatment of HR-positive, HER2-negative breast cancer. Syros Pharmaceuticals hopes its investigational drug targeting another member of the CDK ...

– Detailed characterization of an oral inhibitor of CDK7 demonstrates potent activity against multiple hematologic and solid tumor cell lines, as monotherapy and in combination with chemotherapies – ...

Malfunctioning of the enzyme CDK7 is crucial to many cancers, making drugs that target it a high priority. Despite some demonstrated success, the mechanism by which these drugs work has been a mystery ...

For organs to develop, grow and regenerate, cells must proliferate. But when that process goes awry, leading to uncontrolled cell growth, cancer can emerge. New CU Boulder research, published in the ...

This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.

Immunohistochemical staining Hematoxylin-Eosin, highlights a malignant proliferate tumor (adnocarcinoma), adipose tissue (abdominal fat) infiltrated by a malignant lesion of pancreatic origin. Nerve ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new ...

SAN ANTONIO -- The addition of the CDK7 inhibitor samuraciclib to fulvestrant (Faslodex) demonstrated encouraging antitumor activity among patients with advanced hormone receptor (HR)-positive breast ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today disclosed new preclinical data showing that AUR102 has potent anti-tumor ...

Stephen has degrees in science (Physics major) and arts (English Literature and the History and Philosophy of Science), as well as a Graduate Diploma in Science Communication. Stephen has degrees in ...